These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 27986376

  • 1. Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment.
    Carriere CH, Kang NH, Niles LP.
    Exp Toxicol Pathol; 2017 Feb; 69(2):109-114. PubMed ID: 27986376
    [Abstract] [Full Text] [Related]

  • 2. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH, Kang NH, Niles LP.
    Neuroscience; 2014 May 16; 267():114-21. PubMed ID: 24613722
    [Abstract] [Full Text] [Related]

  • 3. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH, Kang NH, Niles LP.
    Brain Res; 2016 Feb 15; 1633():115-125. PubMed ID: 26740407
    [Abstract] [Full Text] [Related]

  • 4. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
    Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E.
    Behav Brain Res; 2013 Apr 15; 243():6-15. PubMed ID: 23295396
    [Abstract] [Full Text] [Related]

  • 5. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB.
    Acta Neuropathol Commun; 2017 Feb 01; 5(1):11. PubMed ID: 28143577
    [Abstract] [Full Text] [Related]

  • 6. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
    Norazit A, Meedeniya AC, Nguyen MN, Mackay-Sim A.
    Brain Res; 2010 Nov 11; 1360():119-29. PubMed ID: 20807515
    [Abstract] [Full Text] [Related]

  • 7. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
    Sherer TB, Kim JH, Betarbet R, Greenamyre JT.
    Exp Neurol; 2003 Jan 11; 179(1):9-16. PubMed ID: 12504863
    [Abstract] [Full Text] [Related]

  • 8. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, Steece-Collier K, Kemp CJ, Celano S, Schulz E, Sandoval IM, Fleming S, Dirr E, Polinski NK, Trojanowski JQ, Lee VM, Sortwell CE.
    Neurobiol Dis; 2015 Oct 11; 82():185-199. PubMed ID: 26093169
    [Abstract] [Full Text] [Related]

  • 9. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.
    Monti B, Gatta V, Piretti F, Raffaelli SS, Virgili M, Contestabile A.
    Neurotox Res; 2010 Feb 11; 17(2):130-41. PubMed ID: 19626387
    [Abstract] [Full Text] [Related]

  • 10. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
    Sindhu KM, Saravanan KS, Mohanakumar KP.
    Brain Res; 2005 Jul 27; 1051(1-2):25-34. PubMed ID: 15992782
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinson's Disease.
    Miyazaki I, Isooka N, Imafuku F, Sun J, Kikuoka R, Furukawa C, Asanuma M.
    Int J Mol Sci; 2020 May 04; 21(9):. PubMed ID: 32375371
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
    Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E.
    Neuroscience; 2012 Feb 17; 203():170-9. PubMed ID: 22198020
    [Abstract] [Full Text] [Related]

  • 16. α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.
    George S, Mok SS, Nurjono M, Ayton S, Finkelstein DI, Masters CL, Li QX, Culvenor JG.
    J Mol Neurosci; 2010 Oct 17; 42(2):243-54. PubMed ID: 20464527
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
    Liu Y, Sun JD, Song LK, Li J, Chu SF, Yuan YH, Chen NH.
    Behav Brain Res; 2015 Nov 01; 294():149-61. PubMed ID: 26239001
    [Abstract] [Full Text] [Related]

  • 19. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
    Caboni P, Sherer TB, Zhang N, Taylor G, Na HM, Greenamyre JT, Casida JE.
    Chem Res Toxicol; 2004 Nov 01; 17(11):1540-8. PubMed ID: 15540952
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.